[
  {
    "ts": null,
    "headline": "AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant",
    "summary": "AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in migraine treatment. Over the last month, AbbVie’s stock price remained relatively flat, mirroring broader market trends. While the positive study results for Atogepant might have added slight upward pressure, this was tempered by overall market volatility influenced by geopolitical tensions and interest rate speculations. Additionally, other developments, such as the promising...",
    "url": "https://finnhub.io/api/news?id=be6834dd98e84c5bd2a758ca259462495817d6a21cd5da79e3ddea55dcd2aad8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750269988,
      "headline": "AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant",
      "id": 135378761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in migraine treatment. Over the last month, AbbVie’s stock price remained relatively flat, mirroring broader market trends. While the positive study results for Atogepant might have added slight upward pressure, this was tempered by overall market volatility influenced by geopolitical tensions and interest rate speculations. Additionally, other developments, such as the promising...",
      "url": "https://finnhub.io/api/news?id=be6834dd98e84c5bd2a758ca259462495817d6a21cd5da79e3ddea55dcd2aad8"
    }
  },
  {
    "ts": null,
    "headline": "GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?",
    "summary": "GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.",
    "url": "https://finnhub.io/api/news?id=547e450da5dab1f49048cfe0f806d54a87f7c3d641b4306da95706f540275b12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750256520,
      "headline": "GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?",
      "id": 135366748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.",
      "url": "https://finnhub.io/api/news?id=547e450da5dab1f49048cfe0f806d54a87f7c3d641b4306da95706f540275b12"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention",
    "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant (QULIPTA® / AQUIPTA®, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with a history of four or more migraine days per month.1",
    "url": "https://finnhub.io/api/news?id=9cad740080bbc4e6338fa2d5b7fdae259397eb908304a49a8734aeaac42ad2ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750245300,
      "headline": "AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention",
      "id": 135353658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant (QULIPTA® / AQUIPTA®, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with a history of four or more migraine days per month.1",
      "url": "https://finnhub.io/api/news?id=9cad740080bbc4e6338fa2d5b7fdae259397eb908304a49a8734aeaac42ad2ba"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?",
    "summary": "Sector ETF report for PJP",
    "url": "https://finnhub.io/api/news?id=f193afb4bc75857dc117197bde8a01acb07e9b2041e0a93a74fb367688559d03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750242007,
      "headline": "Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?",
      "id": 135353659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Sector ETF report for PJP",
      "url": "https://finnhub.io/api/news?id=f193afb4bc75857dc117197bde8a01acb07e9b2041e0a93a74fb367688559d03"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces New Data Demonstrating Atogepant (QULIPTA®?) Achieves Superiority Across All Endpoints in Phase 3 Head-To-Head Study Compared to Topiram for Migraine Prevention",
    "summary": "AbbVie announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant compared to...",
    "url": "https://finnhub.io/api/news?id=b0da70f414605d6950e55f4464bfb629f05e0944564ecb417453283511612fe6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750241134,
      "headline": "AbbVie Announces New Data Demonstrating Atogepant (QULIPTA®?) Achieves Superiority Across All Endpoints in Phase 3 Head-To-Head Study Compared to Topiram for Migraine Prevention",
      "id": 135356278,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant compared to...",
      "url": "https://finnhub.io/api/news?id=b0da70f414605d6950e55f4464bfb629f05e0944564ecb417453283511612fe6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's migraine drug meets main goal in head-to-head study with topiramate",
    "summary": "AbbVie said on Wednesdayits migraine drug met the main goal and was superior to a widelyused generic treatment in a head-to head late-stage trial. The U.S. drugmaker has been expanding...",
    "url": "https://finnhub.io/api/news?id=f84bf2c7f6e9daa467aa615d5d7914f3786c10940592b6057c7dbdb3032e3581",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750234218,
      "headline": "AbbVie's migraine drug meets main goal in head-to-head study with topiramate",
      "id": 135353057,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie said on Wednesdayits migraine drug met the main goal and was superior to a widelyused generic treatment in a head-to head late-stage trial. The U.S. drugmaker has been expanding...",
      "url": "https://finnhub.io/api/news?id=f84bf2c7f6e9daa467aa615d5d7914f3786c10940592b6057c7dbdb3032e3581"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's migraine drug meets main goal of late-stage study",
    "summary": "AbbVie said on Wednesdayits migraine drug met the main goal and was superior to ageneric drug in a head-to head late-stage trial.(Reporting by Sriparna Roy in Bengaluru; Editing by...",
    "url": "https://finnhub.io/api/news?id=136bb07d2afece062ec5b0e006f01b11c66bc8dab0f1e225301ca17fbe05e0dd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750231513,
      "headline": "AbbVie's migraine drug meets main goal of late-stage study",
      "id": 135352741,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie said on Wednesdayits migraine drug met the main goal and was superior to ageneric drug in a head-to head late-stage trial.(Reporting by Sriparna Roy in Bengaluru; Editing by...",
      "url": "https://finnhub.io/api/news?id=136bb07d2afece062ec5b0e006f01b11c66bc8dab0f1e225301ca17fbe05e0dd"
    }
  }
]